Oxigene May 2026

In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline

On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN).

The shift to Mateon Therapeutics reflected a broader focus on "Vascular Targeted Therapy" (VTT), which combines VDAs with anti-angiogenic agents to trap and destroy tumor cores while preventing new vessel growth. Historical Acquisitions: Oxigene

Unlike traditional anti-angiogenic drugs that prevent new vessel formation, OXiGENE’s VDAs targeted existing immature blood vessels within tumors. These agents compromise the tumor's core vasculature, leading to extensive necrosis (cell death) within the center of the tumor.

A key Phase II trial showed that a combination of CA4P and Avastin significantly improved progression-free survival in ovarian cancer patients compared to Avastin alone. In 2009, OXiGENE re-acquired full rights to its

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)

A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration Acute Myeloid Leukemia (AML)

OXiGENE, Inc. was a clinical-stage biopharmaceutical company that rebranded as in June 2016. The company specialized in developing Vascular Disrupting Agents (VDAs) designed to selectively dismantle blood vessels that sustain solid tumors and contribute to visual impairment. Corporate Evolution